Left Atrial Appendage Exclusion
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
AtriCureAtriCure LAA Exclusion System
MedtronicPenditure™ Left Atrial Appendage
Clinical Trials (2)
Total enrollment: 268 patients across 2 trials
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Start: Sep 2008Est. completion: Oct 201170 patients
Phase 2Completed
CLIP-IT Post-Market Study
Start: Feb 2024Est. completion: Feb 2029198 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.